The First of Five Architectural Masterpieces at The Case, Malibu’s Only New Guard Gate Community in Decades, Lists for $69.995 Million
16.6.2022 00:51:00 EEST | Business Wire | Press release
After more than a decade in approvals, design, and construction, Scott Gillen, visionary home designer, creator and founder of Unvarnished, has listed for sale the first of five estates in the 24-acre private enclave known as The Case. The first guard gated community built in Malibu in decades, The Case comprises five spectacular mid-century modern inspired homes perched above The Colony on Malibu’s most coveted oceanfront bluff and represents the largest private residential development in its history. The Edge, on the market for $69.995 million, will be the first home completed within the community and will be delivered turnkey, providing the buyer instant gratification of unprecedented luxury and hand-crafted design perfection. All five bespoke homes are currently under construction, with the remaining homes slated for full completion throughout the year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615006048/en/
The Edge (Photo: Business Wire)
“The Case is my largest and most epic project to date. The opportunity to create a community of five homes on one of, if not the best bluff top on the California coast, was something I could not pass up. Frankly, ten minutes after I stepped on the property, I knew I would buy it,” said Scott Gillen, the founder of Unvarnished. “The sheer size of the property and the ability to build 10,000 to 12,000-square foot single story homes created immense challenges and unbelievable opportunities for me to take some of my foundational design principles--use of warm natural materials, a nod toward mid-century modern, large, opened spaces, lots of natural light and blurring the line between indoors and out-- which are also tenets of mid-century modern architecture--to the next level. So, it was natural that my designs for The Edge, and the other homes at The Case, take enormous inspiration from mid-century modern architecture, and then I incorporate construction techniques and furnishings, the quality of which are rarely, if ever, found in new development, to create a unique experience of luxury living on the coast of Malibu, a place unlike anywhere else in the world. I’m very proud of how The Edge has turned out and I’m incredibly excited to bring it to market.”
The 2.6-acre estate, providing cinematic views of the Queen’s necklace, Palos Verdes to Point Dume, embodies the essence of casual luxury living. Spanning approximately 10,500 square feet, the single-story home offers five ensuite bedrooms and three half baths, and includes a Bulthaup chef’s kitchen, expansive great room, a master bedroom with outdoor spa, and floor to ceiling glass doors that open to a 10,000-square foot Ipe deck with cabana and outdoor kitchen.
The Edge, named for its stunning nearly 80-foot double-sided infinity edge freshwater pool that juts out like a diving board into the Pacific Ocean, with famed Catalina Island in the distance, is architecturally inspired by the giants of mid-century modern, Lloyd Wright, Neutra, Lautner and Quincy Jones, to name but a few. The magnificent home also includes hand-picked custom furnishings by Minotti and Gillen, Miele and Gaggenau appliances, custom cabinets, a 650-bottle teak wine room, a glass and teak enclosed private library, and a home theatre that is a room “floating” inside another room to achieve the ultimate home cinema experience.
The Case is the crown jewel of Scott Gillen’s visionary Malibu Series, where each home is a sanctuary unto itself. Behind its 24-hour manned guard gate and security features designed by international renowned security expert Gavin de Becker, residents of The Case will live with ultimate peace of mind and privacy.
The Case comprises five distinct mid-century modern homes: The Cantilever House (Case Study No. 1), The Butterfly House (Case Study No. 2), The Edge (Case Study No. 3), The Flat House (Case Study No. 4) and The Glass Tunnel (Case Study No. 5).
For more information, visit www.unvarnishedco.com or contact listing agent Sandro Dazzan of The Agency.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615006048/en/
Contact information
Emily Warner
Murphy O’Brien Public Relations
unvarnishedcopr@murphyobrien.com
310.453.2539
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 15:01:00 EEST | Press release
Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps, supplying inhibitors, biocides and PH control additives. Hyper scale datacenters require new type of cooling solutions. In today’s liquid-cooled data centers, coolant quality and water treatment is becoming a rising issue. Left unmanaged, chemistry drift quietly takes away cooling pe
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 15:00:00 EEST | Press release
STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executing in “a structurally challenged print market.” Since our September letter, we’ve continued to actively engage with Xerox, including at the recent PRINTING United Expo in Las Vegas, and our conversations have been encouraging. We greatly appreciate the willin
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data include an oral proffered paper presentation on BeOne’s GPC3x4-1BB bispecific antibody, currently being studied in hepatocellular carcinoma (HCC) and first-in-human data for two investigational lung cancer assets, a CEA targeting antibody-drug conjugate (ADC), in CEA-expressing non-small cell lung cancer (NSCLC), and a brain-penetrant PRMT5 inhibitor in MTAP-deleted tumors, inclu
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Experts in Vienna19.10.2026 13:00:00 EEST | Press release
Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent challenge: transforming Europe's data centre energy landscape. We brought together leaders from across the data ce
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO ® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 12:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically relevant target in the treatment of moderate to severe ulcerative colitis.1 Results were presented during late-breaker and poster sessions at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal. “There has been increasing conversation about whether achieving deeper levels of remission – addressing both visible and microscopic inflammation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
